SELLAS Life Sciences to Present at the JMP Securities Life Sciences Conference on June 15th
June 02, 2022 08:30 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range...
SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer
May 26, 2022 08:30 ET
|
SELLAS Life Sciences Group, Inc.
- Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone - - Disease Control Rate for GPS combination (GPS plus Keytruda) is 53.9 percent compared to 37.2 percent in a...
SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022 16:12 ET
|
SELLAS Life Sciences Group, Inc.
- Enhanced Pipeline with New Asset, GFH009, an In-licensed Next-Generation, Highly Selective CDK9 Inhibitor - - $25 Million of Gross Proceeds from Capital Raise in April 2022 and $1 Million Milestone...
SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S
April 26, 2022 08:30 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study
April 11, 2022 08:15 ET
|
SELLAS Life Sciences Group, Inc.
- Fifth Dose Level Cohort of GFH009, a Highly Selective CDK9 Inhibitor, Initiated - - No Dose-Limiting Toxicities in First Four Dose Levels - NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) --...
SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China
April 06, 2022 07:00 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Provides Business Update and First Quarter 2022 Highlights
April 05, 2022 16:51 ET
|
SELLAS Life Sciences Group, Inc.
– In-licensed Next-Generation, Highly Selective CDK9 Inhibitor – – Closed Underwritten Public Offering with Gross Proceeds of $25 Million – – Appointed Robert Francomano as Chief Commercial...
SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering
March 31, 2022 21:03 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Announces Proposed Underwritten Public Offering
March 31, 2022 16:11 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Signs Exclusive License Agreement with GenFleet Therapeutics for Next-Generation, Highly Selective CDK9 Inhibitor
March 31, 2022 16:08 ET
|
SELLAS Life Sciences Group, Inc.
- SELLAS In-licenses Worldwide Rights Outside of Greater China for Clinical-Stage Asset - - Completion of Ongoing Phase 1 Trial in the United States/China Expected by Q4 2022 in Relapsed and/or...